Novo Nordisk owner buys majority stake in Austrian life science tools company
Winners and losers in biopharma’s Q1 2024 earnings season
As sales of weight loss drugs skyrocket, the insulin market falters
Eisai starts rolling submission for injectable version of Alzheimer's drug with FDA
*please scroll down for all the latest news*
